Ashwagandha is the world's best-selling botanical. It also can't clear the EU market cleanly. If you're planning a supplement range for Europe, that contradiction is worth understanding before you commit a formula — not after a shipment is stopped at customs.
What the Novel Food Regulation actually says
Under the EU's Novel Food Regulation ((EU) 2015/2283), any food or ingredient without a documented history of significant human consumption within the EU before 15 May 1997 is treated as a "novel food" and requires authorisation before it can be sold. The burden of proof sits with the applicant: you have to demonstrate either that pre-1997 consumption history, or complete a safety authorisation.
Ashwagandha (Withania somnifera) has not cleared that bar as a general food supplement ingredient across the EU. It's a traditional Ayurvedic botanical with deep history in India — but "widely used elsewhere" carries no legal weight at an EU border. What matters is the EU-specific record.
It's not uniform — several states go further
On top of the EU-wide novel-food question, individual member states have taken their own restrictive positions. France, Denmark, and Belgium have moved to restrict or prohibit ashwagandha in food supplements, and it has been flagged for review in Germany. Some national authorities cite safety assessments around liver and hormonal effects. For a brand, the practical result is a patchwork: even where you think you have a route, a specific market may close it.
This is why the safe operating assumption for Europe is simple: do not build your EU range around ashwagandha.
The mistake isn't wanting Indian botanicals in Europe
It's assuming what sells in the US will transfer. The US (under DSHEA) and the EU treat botanicals through completely different regulatory logic. A best-seller on Amazon US can be a non-starter in Germany. Market entry has to start from the destination's rulebook, then work back to the formula — never the other way around.
What to sell instead: the EU-compliant Indian botanicals
The good news is that India supplies plenty of botanicals with a workable EU path and genuine consumer demand. Three stand out for building a credible clean-label range:
- Curcumin (from turmeric), with a bioavailability enhancer. Turmeric has established EU food use; the story (joint comfort, everyday anti-inflammatory support) is strong, and the real differentiator is absorption — plain curcumin is poorly absorbed, so a bioavailability-enhanced format is what makes it work. Keep claims within authorised wording.
- Spirulina. A nutrient-dense algae with established EU food use, an easy "whole-food" narrative, and natural appeal to plant-based and clean-label buyers.
- CoQ10. Well-understood, widely sold in the EU, with a cellular-energy and healthy-aging positioning — and a format story (soft gels absorb better than dry capsules) that lets you sell on quality rather than price.
You can build a genuinely differentiated, clean-label Indian-botanical range for Europe. You just build it from the ingredients that belong there — with the dossiers to prove it.
The deeper principle
Compliance isn't the paperwork you do at the end. It's the first design decision. Choose EU-legal ingredients, verify claims against authorised wording, confirm labelling and any restricted-substance watchlist issues, and hold the documentation before a product moves. Get that order right and Europe becomes an opportunity most competitors avoid because they find the complexity intimidating.
For clarity on how we work: Anarvah is not a manufacturer. We own the formulation and market-specific compliance layer and produce through vetted, GMP-certified partners. For Europe, we keep ashwagandha out of the catalogue by design and lead with the EU-safe botanicals plus their dossiers.
This article is general information, not regulatory or legal advice. Confirm current requirements for each target market before launch.